富国生物医药科技混合C(011308)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
-9,935,595.04 |
166,220,109.38 |
137,422,272.77 |
-122,550,240.41 |
| 利息合计 |
75,318.80 |
218,673.15 |
102,976.28 |
279,009.99 |
| 其中:存款利息收入 |
75,318.80 |
218,673.15 |
102,976.28 |
279,009.99 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-23,641,128.64 |
133,115,204.57 |
-2,215,590.76 |
-62,053,813.39 |
| 其中:股票投资收益 |
-23,067,694.78 |
130,389,426.69 |
-3,535,968.89 |
-70,272,295.47 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
-1,907,335.41 |
80,615.74 |
-459,402.52 |
1,087,813.50 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
1,333,901.55 |
2,645,162.14 |
1,779,780.65 |
7,130,668.58 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
13,347,398.16 |
32,350,267.65 |
139,332,821.87 |
-61,106,391.88 |
| 其他收入 |
282,816.64 |
535,964.01 |
202,065.38 |
330,954.87 |
| 费用 |
3,237,111.18 |
7,807,096.46 |
3,729,786.70 |
9,545,838.96 |
| 管理人报酬 |
2,556,222.92 |
6,316,439.27 |
3,034,436.15 |
7,744,811.42 |
| 基金托管费 |
426,037.22 |
1,052,739.88 |
505,739.35 |
1,290,802.04 |
| 销售服务费 |
160,061.92 |
240,450.07 |
93,522.03 |
323,906.45 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
94,659.73 |
197,401.31 |
96,067.71 |
186,304.88 |
| 利润总额 |
-13,172,706.22 |
158,413,012.92 |
133,692,486.07 |
-132,096,079.37 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年